BioNTech (BNTX)
(Real Time Quote from BATS)
$102.92 USD
-0.99 (-0.95%)
Updated Nov 3, 2025 12:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its growth rate over the past 12 months. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BNTX 102.92 -0.99(-0.95%)
Will BNTX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.

Zacks News for BNTX
BioNTech SE Sponsored ADR (BNTX) Is Up 4.81% in One Week: What You Should Know
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for BNTX
BioNTech price target lowered to $181 from $185 at Clear Street
BioNTech price target lowered by $4 at Clear Street, here's why
BioNTech SE (BNTX) Q3 2025 Earnings Call Transcript
BioNTech SE 2025 Q3 - Results - Earnings Call Presentation
BioNTech (BNTX) Revises 2025 Capital Expenditure Projections